Advanced Hepatocellular Carcinoma in A Scottish
Population – Current Experience and the Future
Volume 1 - Issue 3
Baxter MA1,2*, Peters AL1, Graham J1,3
-
Author Information
Open or Close
- 11Beatson West of Scotland Cancer Centre, Glasgow, UK
- 2University of Dundee, UK
- 3University of Glasgow, UK
*Corresponding author:
Dr Mark A Baxter, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, 1053 Great
Western Road, Glasgow, UK
Received: August 07, 2018; Published: August 10, 2018
DOI: 10.32474/CTGH.2018.01.000112
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other
drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in
a Scottish population as well as discuss the evidence behind new potential therapies.
Keywords: Sorafenib; Hepatocellular carcinoma; HCC
Abbreviations: HCC: Hepatocellular Carcinoma; PS: Performance Status; OS: Overall Survival; TACE: Transarterial
Chemoembolization; VEGF: Vascular Endothelial Growth Factor; PDGFR: Platelet Derived Growth Factor Receptor; FGFR: Fibroblast
Growth Factor Receptor; WoS: West of Scotland
Abstract|
Introduction|
Results and Discussion|
Conclusion|
References|